25 March 2024
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.